OS Therapies' OST-HER2 Nears FDA Accelerated Approval for Osteosarcoma Amidst ASCO Data Presentation

OS Therapies' OST-HER2 Nears FDA Accelerated Approval for Osteosarcoma Amidst ASCO Data Presentation

OST-HER2 osteosarcoma immunotherapy seeks FDA accelerated approval as OS Therapies pushes the program through a rolling BLA submission. OS Therapies is advancing OST-HER2, an immunotherapy for osteosarcoma, towards FDA accelerated approval. The company anticipates presenting crucial survival data at ASCO 2026, aligning with its planned 2026 Biologics License Application (BLA) submission. With three FDA designations already secured, a rolling BLA underway, and a pivotal survival readout on the horizon, OST-HER2 represents one of the most consequential near-term catalysts in rare pediatric oncology.

Key Takeaways

• OST-HER2 osteosarcoma immunotherapy seeks FDA accelerated approval; OS Therapies has initiated a rolling BLA submission in 2026, with a complete filing targeted within the year.
• The company will present 2.5-year overall survival data from its Phase 2b trial at ASCO 2026 — a pivotal readout underpinning the accelerated approval case.
• OST-HER2 holds three FDA designations: Orphan Drug Designation (ODD), Fast Track Designation (FTD), and Rare Pediatric Disease Designation (RPDD).
• OS Therapies completed an End of Phase 2 meeting with the FDA and has separately applied for Regenerative Medicine Advanced Therapy (RMAT) designation.
• Four peer-reviewed articles on OST-HER2 were published in Drug Discovery World, reinforcing the scientific foundation ahead of the ASCO 2026 data presentation.

What Is OST-HER2 and Why Does the Osteosarcoma Market Need It?

Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. For patients with recurrent or metastatic disease, five-year survival rates remain below 30%, and no approved maintenance therapies exist to prevent recurrence after surgical resection of pulmonary metastases. OST-HER2 (OST31-164) is an investigational cell-based immunotherapy designed to fill that gap — targeting HER2, a receptor overexpressed in a subset of osteosarcoma tumors, to stimulate an anti-tumor immune response in the maintenance setting.

The Phase 2b trial (NCT04974008) is an open-label, multicenter, single-arm study enrolling patients aged 12 to 39 with fully resected pulmonary recurrent osteosarcoma. The trial's design — focused on preventing or delaying recurrence after surgery — directly addresses the most pressing unmet need in this population. There is virtually no competitive pipeline in the osteosarcoma maintenance space, which gives OST-HER2 a clear regulatory and commercial runway if the survival data hold up.

How Is OS Therapies Building Its Regulatory Case with the FDA?

The regulatory architecture around OST-HER2 is unusually layered for a company of OS Therapies' size. The FDA granted Orphan Drug, Fast Track, and Rare Pediatric Disease designations — a triad that unlocks expedited review pathways, increased FDA engagement, and a transferable priority review voucher upon approval under the RPDD. The company secured an End of Phase 2 meeting with the agency to align on the OST-HER2 program structure for the prevention or delay of disease recurrence, and subsequently began a rolling BLA submission, allowing completed modules to be filed as they are finalized rather than waiting for the entire dossier.

OS Therapies has also applied for RMAT designation, which would provide additional opportunities for intensive FDA guidance typically reserved for regenerative medicine products. Whether or not RMAT is granted, the existing designations already provide a meaningful acceleration framework. The FDA has engaged with the company on biomarker data discussions under its plausible mechanism framework — an approach the agency has shown willingness to apply to OST-HER2, allowing surrogate or intermediate endpoints that are reasonably likely to predict clinical benefit. That framework is particularly relevant in rare pediatric cancers where large randomized trials are impractical.

Four peer-reviewed articles on OST-HER2 were published in Drug Discovery World, timed to coincide with ASCO 2026 preparation. This coordinated publication strategy builds peer-reviewed scientific credibility and primes the clinical audience before the headline data are presented. The publications reinforce the mechanistic narrative supporting OST-HER2's differentiated approach in the maintenance setting.

What Could the ASCO 2026 Survival Data Unlock for OST-HER2?

The 2.5-year overall survival data from the Phase 2b trial, slated for presentation at ASCO 2026, is the single most important near-term catalyst. Overall survival is the gold-standard endpoint for accelerated approval in oncology. Demonstrating a meaningful survival signal in a maintenance setting — where patients have already undergone aggressive multi-agent chemotherapy and complete surgical resection of metastases — would substantially strengthen the BLA and could support a rapid approval decision.

Analyses of the FDA's accelerated approval pathway in oncology, including real-world studies of oncology accelerated approvals, underscore that the mechanism was designed precisely for scenarios like this: serious or life-threatening conditions with clear unmet need, where a surrogate or intermediate clinical endpoint can expedite patient access. For OST-HER2, the 2.5-year survival data serves as that critical bridge. If the numbers are compelling, the rolling BLA structure means the FDA could act on a near-complete application within months of filing, rather than the standard 10-to-12-month review clock.

The ASCO 2026 presentation also carries signaling value beyond the immediate regulatory question. It will be the first major public forum where the full survival curve is scrutinized by the oncology community — and by potential partners or acquirers evaluating the asset's commercial potential. A strong readout could accelerate partnership discussions or attract acquisition interest from larger oncology players seeking to build pediatric franchises.

What Should BD Teams and Investors Watch Next?

For business development teams, OST-HER2 checks several boxes that make it a high-priority tracking asset: late-stage data approaching, multiple regulatory designations, a clean competitive field in osteosarcoma maintenance, and a Rare Pediatric Disease Designation that carries a transferable priority review voucher potentially worth several hundred million dollars. Companies building pediatric oncology portfolios should have OS Therapies on their radar screens now, before the ASCO 2026 data reshape the competitive calculus.

Investors should focus on three milestones in sequence. First, the ASCO 2026 survival readout — positive data de-risk the accelerated approval thesis and could trigger a significant re-rating of OSTX. Second, the completion of the rolling BLA submission, which sets a formal clock on FDA review. Third, the FDA's decision on the RMAT designation request, which, while not essential, would add another layer of regulatory optionality. The RPDD-linked priority review voucher is an often-underappreciated source of non-dilutive value that could materially change the company's strategic options post-approval.

More broadly, OST-HER2's trajectory signals that the FDA remains receptive to accelerated approval arguments in rare pediatric cancers supported by single-arm data, biomarker engagement, and a clear unmet need. That has read-across implications for other companies developing therapies in similar orphan oncology niches — the plausible mechanism framework is lowering the evidentiary bar for approval, and OS Therapies is testing exactly how far that flexibility extends.

Frequently Asked Questions

Related coverage

• OS Therapies Publishes Four Articles on OST-HER2 and Osteosarcoma, Signaling Clinical Progress
• Cancer Therapy OST-HER2 Faces 2026 EMA Call After Survival Data
• BioCryst Presents New HAE Data for ORLADEYO® and Navenibart at EAACI 2026